RGNX REGENXBIO Inc.

NASDAQ
$10.77

REGENXBIO Inc. (RGNX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $1.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.6% since its last earnings release on August 6, 2026.

REGENXBIO Beat Consensus Estimates
Thursday, August 6, 2026 · 7:05 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 7:10 AM ET
Earnings Whisper
-
vs ($1.36)
Rev est $37.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.82

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Sector

Healthcare

Industry

Biotechnology